Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

Details

Ressource 1Download: serval:BIB_BEEC4DDFA954.P001 (124.41 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_BEEC4DDFA954
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles
Journal
Journal of the National Cancer Institute
Author(s)
Nardelli-Haefliger  D., Wirthner  D., Schiller  J. T., Lowy  D. R., Hildesheim  A., Ponci  F., De Grandi  P.
ISSN
1460-2105 (Electronic)
Publication state
Published
Issued date
08/2003
Volume
95
Number
15
Pages
1128-37
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Aug 6
Abstract
BACKGROUND: In early-phase trials, a human papillomavirus 16 (HPV16) virus-like particle (VLP) vaccine has been shown to be well tolerated, immunogenic, and protective against HPV16 in women, most of whom were taking oral contraceptives. Previous studies have not determined whether HPV immunization results in specific antibody levels in the human genital tract or whether these levels might vary during contraceptive or ovulatory cycles. Therefore, we determined the levels of total and specific antibodies in the cervical secretions of women who had been immunized with HPV16 VLPs and examined the influence of the menstrual cycle and oral contraceptive use on these levels. METHODS: Two groups of women were immunized, seven who were taking oral contraceptives and 11 who were ovulating. After seroconversion, serum and cervical secretions were collected twice weekly for 5 weeks. Total immunoglobulins (IgG and IgA) and vaccine-specific IgGs were determined by enzyme-linked immunosorbent assay. Nonparametric statistical analyses were used to determine the statistical significance of differences in IgG levels between groups, and correlations between serum- and cervical-specific IgG levels were determined by the Spearman correlation coefficient. RESULTS: All participants developed detectable titers of anti-HPV16 VLP IgGs in their cervical secretions after immunization. The cervical titers of specific IgG and total IgGs and IgAs among participants in the contraceptive group were relatively constant throughout the contraceptive cycle. In contrast, the cervical titers of specific IgG and total IgGs and IgAs among participants in the ovulatory group varied during the menstrual cycle, being highest during the proliferative phase, decreasing approximately ninefold around ovulation, and increasing approximately threefold during the luteal phase. Serum- and cervical-specific IgG levels were correlated (r =.86) in women in the contraceptive group but not in women in the ovulatory group (r =.27). CONCLUSIONS: The relatively high titer of anti-HPV16 antibodies at the cervix is promising in terms of vaccine efficacy; however, the decrease in antibody titer around ovulation raises the possibility that the HPV16 VLP vaccine might be less effective during the peri-ovulatory phase.
Keywords
Antibodies, Viral/*analysis Cervix Uteri/*immunology Contraceptives, Oral, Hormonal/administration & dosage Enzyme-Linked Immunosorbent Assay Female Humans Immunoglobulin A/analysis Immunoglobulin G/analysis Menstrual Cycle/*immunology Ovulation Papillomaviridae/*immunology Viral Vaccines/*administration & dosage Virion/immunology
Pubmed
Web of science
Open Access
Yes
Create date
25/01/2008 16:39
Last modification date
25/09/2019 7:10
Usage data